Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 5Breast 5Head & Neck 3Thoracic 2Other hematologic neoplasm 2Genitourinary 2Gastrointestinal 2Tumor-Agnostic 1Gynecologic 1Dermatologic 1

Conditions

Uterine Cervical Neoplasms 1Recurrence 1

Interventions

Paclitaxel 77pembrolizumab 59Carboplatin 57Bevacizumab 57Specimen Handling 48Magnetic Resonance Spectroscopy 39Cisplatin 32olaparib 31Gemcitabine 25liposomal doxorubicin 24Biopsy 20Taxes 19Topotecan 17Nivolumab 17Cyclophosphamide 16Immunoglobulin G 15Doxorubicin 15Disulfides 15niraparib 12fludarabine 12Surveys and Questionnaires 12Letrozole 12lenvatinib 11durvalumab 11atezolizumab 11Fulvestrant 10Drug Therapy 10abemaciclib 9Docetaxel 9Brachytherapy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Therapeutics × Gynecologic × 90 days × Clear all
NCT07542717 2026-04-21

ASCERV Study: MRG003 Combined With QL1706 in Recurrent or Metastatic Cervical Cancer

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 1/2 Not yet recruiting
41 enrolled
Gynecologic

Uterine Cervical Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡